Thomas J. Bell, PhDDirector of Scientific Service

MISSION STATEMENT

To serve the research community and to advance research and discovery through the procurement and distribution of organs, tissues and other biospecimens.

Serving more than 5,000 researchers with over 300,000 biospecimens resulting in 2,500 publications

NDRI Program Since 1980

Funded by NIH for~30 Consecutive Years

NIHOffice of the

DirectorDPCPSI

NCI

OD

NIDDK

NIAID

NEI

ORDR

NHGRI

NIMH

NHLBI

NIAMS

Corporate Funding • Pharma/biotech industry• Provided tissues to > 330 for-profit entities in last 5 years

Special Initiative Funding• Cystic Fibrosis Foundation Collaboration• PA State Formula Grant Funding• Joslin Medalist Project

 

Additional Funding

Flow of Biospecimens to Scientists

NDRI Team 24/7

~41,000

Offered Tissues

Nationally

~3,700

Diseased Tissues

82 Types

~1,311

Tissues Banked

~13,003

Tissues Matched &

Placed

NDRI Researchers ~700 USA Researchers

Hawaii1

Alabama2

Arkansas4

California109

Arizona3

Colorado2

Connecticut10

DC1

New Jersey16

Delaware3

Florida13

Georgia10

Indiana8

Illinois20

Iowa3

Kansas3 Kentuck

y4

Louisiana4

Mass.77

Maryland57

Maine1

Michigan11

Minnesota

13

Missouri8

Montana1

North Carolina

16

Nebraska4

New Hampshir

e1

New Mexico2

New York50

Ohio27

Oklahoma3

Oregon4

Pennsylvania51

Rhode Island

2

South Carolina

4

Tennessee

10

Texas27

Utah2

Virginia10

Vermont1

Washington13

Wisconsin10

Miss.1

West Virginia

1

NDRI Global Researchers 101 International Researchers18 Countries 2012

Australia5

Austria1

Belgium2

Canada37

Denmark1

Finland1

France3

Germany5

India1

Ireland1

Israel4Italy

2

Japan3

Netherlands1

Scotland1

Switzerland4

Taiwan1

United Kingdom

27

United States640

NDRI National Networks- 240 Sites

56 Organ Procurement Organizations

37 Eye Banks

23 Tissue Banks

18 Remote Sites

60 Recovery Personnel

46 Hospital Donor Sites

Researcher Application Process

1. Application- IRB document- Project synopsis- CV/Biosketch- Signed applicant’s agreement

2. Internal Feasibility Committee Review3. External Feasibility Committee Review

4. Customized protocol development- Researcher-specified parameters

• NDRI program approved by UPenn IRB

• Research – unrestricted

• Permission to use:- For profit - Therapeutics or diagnostics

- Genome sequencing

• Potential access to complete health record

Consent and Authorization

Researchers Diversity

Digestive

Medical Devices

Neuroscience

Ocular

Endocrine

Cell Biology

Cardiovascular

Immunology

Rare Disease

Musculoskeletal

Renal

Reproductive

RespiratoryBloodCancer

Dorsal Root Ganglia

• ~120 Peer-reviewed Publications - Cell - PNAS - Molecular Cell

• ~849 authors • ~89 research centers/ institutes

Publications Diversity

• Low-PMI Biospecimens

• Normal and Diseased– Common and Rare

• High Quality Non-transplantable Organs

• Cancer Tumors/Normal Adjacent Tissues

• Cord Blood/Placenta/Umbilical Cord

• HIV+ Tissues

Biospecimen Diversity

Source Diversity*

Standard Requests

• Ocular Tissue

• Transplant Organs

• Autopsy Specimens

• Surgical Specimens

Project-specific Requests

• Specialized Sourcing

• Special Initiatives• Eye Slide Program• Sympathetic and Dorsal

Root Ganglia

*All Source Partners are AATB or AOPO Accredited

• Pre- and post-opt blood and fluid samples

• Medical questionnaire and chart review

• Rapid preservation intervals(<1 hour)

• Rapid delivery intervals (<24 hours)

Musculoskeletal sample highlights

• Two new drugs developed in collaboration with the Cystic Fibrosis Foundation and Vertex Pharmaceuticals

• NDRI provided 166 CF lungs for R&D Program

Kalydeco FDA approved, and VX809/Kalydeco in Clinical Trials

“Almost every primary cell used in the Vertex discovery was from an NDRI lung”

Chris Penland PhDDirector of Research, Cystic Fibrosis Foundation

Bench to Bedside Success

Project-driven service to scientists

Nationwide tissue source sites

Worldwide distribution capabilities

Diseased and normal biospecimens available from multiple donor types

SOPs in place for consent, recovery, & distribution to academic and corporate scientists

NDRI Summary

Please stop booth #421!

Thomas Bell, PhDDirector of Scientific Services

tbell@ndriresource.org1-800-222-NDRI

Mike SalvatoreDirector of Site Management

msalvatore@ndriresource.org1-800-222-NDRI

Thank you